Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-09-05, Stock:PFE, The news for the past five days is as follows:
2018-08-28: NEWS1: 3 ETFs for Johnson & Johnson's Healthy Breakout.NEWS2: Pfizer Recalls Children's Advil Recall Due To Overdose Concerns.NEWS3: Pfizer Recalls Children's Advil Recall Due To Overdose Concerns.NEWS4: Why Ionis Pharmaceuticals Stock Is Plummeting Today.NEWS5: Pfizer's Tafamidis Fails to Impress in Cardiomyopathy Study.NEWS6: Pfizer's Tafamidis Fails to Impress in Cardiomyopathy Study.NEWS7: Notable ETF Inflow Detected - IWB, UNH, PFE, CVX.NEWS8: Notable ETF Inflow Detected - IWB, UNH, PFE, CVX.NEWS9: 6 Things Alnylam Investors Need to Know About Pfizer's Next Blockbuster Drug.NEWS10: 6 Things Alnylam Investors Need to Know About Pfizer's Next Blockbuster Drug.NEWS11: Pfizer&apos;s Tafamidis Fails to Impress in Cardiomyopathy Study.NEWS12: This Is Like Buying in March 2009 and Knowing What Happens Next.NEWS13: This Is Like Buying in March 2009 and Knowing What Happens Next.NEWS14: 6 Things Alnylam Investors Need to Know About Pfizer&apos;s Next Blockbuster Drug.NEWS15: Pfizer stock drops 2% as positive rare-disease drug results won’t stop competitors.NEWS16: Why Alnylam Pharmaceuticals Stock Rose ~16% Yesterday.NEWS17: Today’s Research Reports on Stocks to Watch: Pfizer and Alnylam Pharmaceuticals.NEWS18: Why Pfizer (PFE) Stock Turned South Today.NEWS19: Why Pfizer (PFE) Stock Turned South Today.
2018-08-29: NEWS1: Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know.NEWS2: Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know.NEWS3: Canadian Trade Hopes, Tech Push Nasdaq, S&P to Record Highs.NEWS4: Canadian Trade Hopes, Tech Push Nasdaq, S&P to Record Highs.NEWS5: Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know.NEWS6: EC Approves Amgen’s Blincyto for Pediatric Patients.NEWS7: Pfizer Stock Up This Year So Far: What's Going in its Favor?.NEWS8: Pfizer Stock Up This Year So Far: What's Going in its Favor?.NEWS9: Pfizer Stock Up This Year So Far: What&apos;s Going in its Favor?.NEWS10: Perrigo Company (PRGO) Ex-Dividend Date Scheduled for August 30, 2018.NEWS11: Perrigo Company (PRGO) Ex-Dividend Date Scheduled for August 30, 2018.
2018-08-30: NEWS1: CRON Goes Up In Smoke On Citron Report, Hot AFMD Is Cooling Now, REPL On Watch.NEWS2: CRON Goes Up In Smoke On Citron Report, Hot AFMD Is Cooling Now, REPL On Watch.NEWS3: U.S. Stocks Snap Four-Day Win Streak on Renewed China Trade Concerns.NEWS4: U.S. Stocks Snap Four-Day Win Streak on Renewed China Trade Concerns.NEWS5: Pfizer’s Quarterly Revenues and Estimates for 2018.NEWS6: Pfizer’s Developments in August.NEWS7: Pfizer (PFE) Up 3.1% Since Last Earnings Report: Can It Continue?.NEWS8: Pfizer (PFE) Up 3.1% Since Last Earnings Report: Can It Continue?.NEWS9: Pfizer’s Stock Performance in August.NEWS10: Scholar Rock stock tumbles 11% as Pfizer discontinues similar medication.NEWS11: Pfizer (PFE) Up 3.1% Since Last Earnings Report: Can It Continue?.NEWS12: Dow Movers: DWDP, PFE.NEWS13: Dow Movers: DWDP, PFE.NEWS14: Amgen&apos;s Leukemia Drug Blincyto Gets EU Nod for Pediatric Use.NEWS15: Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?.NEWS16: Pfizer stops developing therapy for the rare disease Duchenne muscular dystrophy.NEWS17: See what the IHS Markit Score report has to say about Pfizer Inc..NEWS18: Pfizer Terminates Domagrozumab (PF-06252616) Clinical Studies for the Treatment of Duchenne Muscular Dystrophy.NEWS19: 3 High-Yield Healthcare Dividend Stocks Still Worth Buying.NEWS20: 3 High-Yield Healthcare Dividend Stocks Still Worth Buying.NEWS21: Pfizer Terminates Two Duchenne Muscular Dystrophy Studies.NEWS22: Pfizer Terminates Two Duchenne Muscular Dystrophy Studies.
2018-08-31: NEWS1: Biotech Fund Flows, Including ETF Activity, Remain a Driver to Watch.NEWS2: After Hours Most Active for Aug 31, 2018 :  MU, AAPL, ILG, CSCO, GE, VAC, QQQ, UIS, MSFT, F, PFE, FDC.NEWS3: After Hours Most Active for Aug 31, 2018 :  MU, AAPL, ILG, CSCO, GE, VAC, QQQ, UIS, MSFT, F, PFE, FDC.NEWS4: How Eli Lilly’s Business Segments Performed in Q2 2018.NEWS5: One sector is beating tech this quarter, but one technician sees a ceiling.NEWS6: Pfizer Discontinues Studies on DMD Candidate Domagrozumab.NEWS7: Pfizer Discontinues Studies on DMD Candidate Domagrozumab.NEWS8: Analyzing Eli Lilly’s Q2 2018 Revenue Trend.NEWS9: Pharma Stock Roundup: Approval of NVS & ABBV Cancer Drugs, MRK's HIV Drug in Focus.NEWS10: Pharma Stock Roundup: Approval of NVS & ABBV Cancer Drugs, MRK's HIV Drug in Focus.NEWS11: Eli Lilly’s Valuation on August 30.NEWS12: Pfizer Discontinues Studies on DMD Candidate Domagrozumab.NEWS13: Pharma Stock Roundup: Approval of NVS & ABBV Cancer Drugs, MRK&apos;s HIV Drug in Focus.NEWS14: Phibro Animal Health Corporation (PAHC) Ex-Dividend Date Scheduled for September 04, 2018.NEWS15: Phibro Animal Health Corporation (PAHC) Ex-Dividend Date Scheduled for September 04, 2018.NEWS16: 4 Large Cap Pharma Stocks in Focus on Robust Cancer Pipeline.NEWS17: See what the IHS Markit Score report has to say about Pfizer Inc..NEWS18: Biotech Stocks Facing FDA Decision In September.NEWS19: Biotech Stocks Facing FDA Decision In September.
2018-09-04: NEWS1: Pfizer Prices $5bln Debt Offering.NEWS2: Pfizer Prices $5bln Debt Offering.NEWS3: Mylan Suffers Several Setbacks: What's in Store in 2H18?.NEWS4: Mylan Suffers Several Setbacks: What's in Store in 2H18?.NEWS5: Better Buy: Pfizer Inc. vs. Eli Lilly and Company.NEWS6: Better Buy: Pfizer Inc. vs. Eli Lilly and Company.NEWS7: TREASURIES-Yields rise as investors prepare for corporate debt supply.NEWS8: Better Buy: Pfizer Inc. vs. Eli Lilly and Company.NEWS9: Mylan Suffers Several Setbacks: What&apos;s in Store in 2H18?.NEWS10: Pfizer says getting ready for Brexit will cost $100m.NEWS11: Pfizer Estimates Brexit Costs at $100 Million as Talks Drag.NEWS12: Pfizer Estimates Brexit Costs at $100 Million as Talks Drag On.

Answer: Rise